Enveric Biosciences Files 8-K, Reports Material Agreement

TL;DR

Enveric Bio (ENVB) filed an 8-K on Jan 30th, reporting a material definitive agreement. Details to follow.

AI Summary

Enveric Biosciences, Inc. filed an 8-K on February 3, 2025, reporting an entry into a material definitive agreement and other events. The filing details the company's corporate structure and historical name changes, including its former names AMERI Holdings, Inc. and SPATIALIZER AUDIO LABORATORIES INC.

Why It Matters

This 8-K filing indicates a significant event for Enveric Biosciences, potentially involving a new contract or partnership that could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in this initial filing warrants a medium risk assessment.

Key Numbers

• 20250130 — Date of Report (Earliest event reported)
• 20250203 — Filing Date (Date the report was filed with the SEC)

Key Players & Entities

• Enveric Biosciences, Inc. (company) — Registrant
• AMERI Holdings, Inc. (company) — Former Company Name
• SPATIALIZER AUDIO LABORATORIES INC (company) — Former Company Name
• 001-38286 (dollar_amount) — SEC File Number
• 95-4484725 (dollar_amount) — I.R.S. Employer Identification No.

FAQ

Key Financial Figures

• $0.01 — ch registered Common stock, par value $0.01 per share ENVB The Nasdaq Stock Mar
• $3 — ach Share and accompanying Warrants was $3.00, and the offering price for each Pre
• $2.9999 — d Warrant and accompanying Warrants was $2.9999. The Pre-Funded Warrants have an exerci
• $0.0001 — nded Warrants have an exercise price of $0.0001 per share, are exercisable immediately
• $3.00 — . Each Warrant has an exercise price of $3.00 per share and will be exercisable immed
• $4.3 million — rcise of the Warrants, is approximately $4.3 million. The Company intends to use the net pro
• $25,000 — a non-accountable expense allowance of $25,000, (iv) reimbursement of up to $100,000 f
• $100,000 — of $25,000, (iv) reimbursement of up to $100,000 for legal fees and expenses and other o
• $15,950 — er out of pocket expenses and (v) up to $15,950 for the clearing expenses. Also pursu
• $3.75 — gent Warrants have an exercise price of $3.75 per share (which represents 125% of the

Filing Documents

• form8-k.htm (8-K) — 54KB
• ex99-1.htm (EX-99.1) — 15KB
• ex99-2.htm (EX-99.2) — 15KB
• 0001493152-25-004715.txt ( ) — 268KB
• envb-20250130.xsd (EX-101.SCH) — 3KB
• envb-20250130_lab.xml (EX-101.LAB) — 33KB
• envb-20250130_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 3, 2025 ENVERIC BIOSCIENCES, INC. By: /s/ Joseph Tucker Joseph Tucker Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR